Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $153.4152W HIGH $212.71
Volume
2.12 M
Value Traded
605.23 M
Short % Float
0.14%
+1.71%Week
-0.28%1 Month
-6.06%3 Month
-21.28%6 Month
+64.22%5 Year
+368.75%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
246.90 B
EPS (TTM)
6.61
P/E Ratio
24.09
Ent. Value
301.56 B
Total Shares
1.55 B
Float Shares
1.50 B
Insiders
3.44%
Institutions
60.85%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AZN Catalyst Timeline
Dated clinical, regulatory and corporate events for AstraZeneca PLC
Catalyst Timeline
Dated clinical, regulatory & corporate events for AstraZeneca PLC
150Total events
14Upcoming
108Tier-1 (high impact)
2015 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Manufacturing MilestoneCMC / Inspection
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
▲Partnership / LicenseCorporate
Daiichi Sankyo and AstraZeneca enter clinical trial collaboration with Summit Therapeutics to evaluate Datroway plus ivonescimab
multiple tumor types including lung and breast cancerssource ↗
▲Milestone PaymentElecoglipronCorporate
Eccogene receives $50M milestone payment from AstraZeneca
▲Partnership / LicenseCorporate
Susan G. Komen and AstraZeneca announce Navigation Infrastructure Collaboration partnership
breast cancersource ↗
▲Partnership / LicenseZEGFROVYApprovedCorporate
AstraZeneca completes global license agreement with Dizal for ZEGFROVY (sunvozertinib)
lung cancersource ↗
▲Trial InitiationElecoglipronTrial
Initiation of Elevate Phase 3 outcome trials of elecoglipron in HFmrEF/HFpEF and CKD
heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and chronic kidney disease (CKD)source ↗
▲FDA ApprovalCamizestrantApprovedFDA Decision
AstraZeneca's camizestrant in combination with CDK 4/6 inhibitor approved in the US
HR+, HER2–, locally advanced or metastatic breast cancer upon detection of ESR1 mutationsource ↗
▲FDA ApprovalLEROCHOLApprovedFDA Decision
FDA approved autoinjector for LEROCHOL and updated prescribing information
reducing risk of major adverse cardiovascular events (MACE) in adults through LDL-C loweringsource ↗
▲Partnership / LicenseZEGFROVYApprovedCorporate
Dizal grants AstraZeneca global exclusive license for Zegfrovy
non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutationssource ↗
●sNDA SubmissionZEGFROVYApprovedRegulatory Filing
sNDA submitted to China CDE for 1st-line indication
first-line NSCLC with EGFR exon20ins mutationssource ↗
▲Breakthrough Therapy DesignationZEGFROVYApprovedDesignation
Breakthrough Therapy Designation granted by China CDE
first-line NSCLC with EGFR exon20ins mutationssource ↗
▲FDA ApprovalZEGFROVYApprovedFDA Decision
Approved in US for 2nd-line NSCLC with EGFR exon20ins
locally advanced or metastatic NSCLC with EGFR exon20ins after platinum chemosource ↗
▲Partnership / LicenseCorporate
Evogene and ELEO announced strategic partnership for oral PCSK9 inhibitors
hyperlipidemia and cardiovascular diseasessource ↗
●sNDA SubmissionZEGFROVYApprovedRegulatory Filing
sNDA submitted to China CDE and US FDA for 1st-line setting
first-line NSCLC with EGFR exon20ins mutationssource ↗
▲Primary Endpoint MetImfinziApprovedClinical Data
Imfinzi VOLGA trial met primary endpoint in MIBC not candidates for cisplatin
MIBC not candidates for cisplatinsource ↗
▼Primary Endpoint MissedImfinziApprovedClinical Data
Imfinzi EMERALD-2 trial did not meet primary endpoint in adjuvant HCC
Adjuvant HCCsource ↗
▲Primary Endpoint Metsone-veClinical Data
sone-ve CLARITY-Gastric01 trial met primary endpoint in 2L+ Cldn18.2+ gastric/GEJ cancer
2L+ Cldn18.2+ gastric/GEJ cancersource ↗
▼Primary Endpoint MissedWainuaApprovedClinical Data
Wainua CARDIO-TTRansform trial did not meet primary endpoint in ATTR-CM
ATTR-CMsource ↗
▼Primary Endpoint MissedUltomirisApprovedClinical Data
Ultomiris TMA-313 trial did not meet primary endpoint in HSCT-TMA (adults)
HSCT-TMA (adults)source ↗
▲Primary Endpoint MetUltomirisApprovedClinical Data
Ultomiris ALXN1210-MG-319 trial met primary endpoint in paediatric gMG
gMG (paediatric)source ↗
▲FDA ApprovalCALQUENCEApprovedFDA Decision
Calquence approved in Japan for 1L CLL (fixed duration)
1L CLL (fixed duration)source ↗
▲FDA ApprovalDatrowayApprovedFDA Decision
Datroway approved in US for 1L TNBC where immunotherapy is not an option
1L TNBC for patients where immunotherapy is not an optionsource ↗
▲FDA ApprovalENHERTUApprovedFDA Decision
Enhertu approved in US for high-risk HER2+ early breast cancer (post-neoadjuvant)
High-risk HER2+ early breast cancer (post-neoadjuvant)source ↗
▲FDA ApprovalCamizestrantApprovedFDA Decision
Etcamah (camizestrant) approved in EU and Japan for ESR1m HR+ HER2- 1L locally advanced or metastatic breast cancer
ESR1m HR+ HER2- 1L locally advanced or metastatic breast cancersource ↗
▲FDA ApprovalImfinziApprovedFDA Decision
Imfinzi approved in Japan for resectable gastric/GEJ cancer
Resectable gastric/GEJ cancersource ↗
▲FDA ApprovalOrphathysApprovedFDA Decision
Orphathys approved in China for 3L+ MET+ gastric/GEJ cancer
3L+ MET+ gastric/GEJ cancersource ↗
▲FDA ApprovalTRUQAPApprovedFDA Decision
Truqap approved in US for PTEN-deficient mHSPC
PTEN-deficient mHSPCsource ↗
▲FDA ApprovalBaxfendyApprovedFDA Decision
Baxfendy approved in US for hypertension
Hypertensionsource ↗
▲FDA ApprovalFasenraApprovedFDA Decision
Fasenra approved in US, EU, Japan and China for hypereosinophilic syndrome
Hypereosinophilic syndromesource ↗
▲FDA Filing AcceptedBaxfendyApprovedRegulatory Filing
Baxfendy regulatory submission accepted in Japan for hypertension
Hypertensionsource ↗
▲FDA Filing AcceptedTozorakimabFiledRegulatory Filing
tozorakimab regulatory submission accepted in EU and China for COPD
COPDsource ↗
▲FDA Filing AcceptedUltomirisApprovedRegulatory Filing
Ultomiris regulatory submission accepted in US and Japan for IgAN
IgANsource ↗
▲FDA Filing Acceptedefzimfotase alfaFiledRegulatory Filing
efzimfotase alfa regulatory submission accepted in Japan for HPP
HPPsource ↗
▲Partnership / LicenseZEGFROVYApprovedCorporate
AstraZeneca entered exclusive license agreement with Dizal for Zegfrovy (sunvozertinib)
lung cancersource ↗
▲Partnership / LicenseTQC3721Corporate
AstraZeneca and CTTQ entered exclusive licence agreement for TQC3721
respiratory indicationssource ↗
◆PDUFA DateDatrowayApprovedRegulatory Filing
PDUFA date set for DATROWAY sBLA in TNBC
metastatic triple negative breast cancersource ↗
▲Late-BreakerZEGFROVYApprovedPresentation
Late-Breaking Abstract Oral Presentation at 2026 ASCO and NEJM publication
first-line NSCLC with EGFR exon20ins mutationssource ↗
▲Oral PresentationZEGFROVYApprovedPresentation
Late-Breaking Abstract Oral Presentation at 2026 ASCO Annual Meeting
first-line NSCLC with EGFR exon20ins mutationssource ↗
▲PublicationZEGFROVYApprovedPresentation
WU-KONG28 results published in New England Journal of Medicine
first-line NSCLC with EGFR exon20ins mutationssource ↗
▲FDA Filing AcceptedgiredestrantFiledRegulatory Filing
US FDA accepted Roche's NDA under Priority Review for giredestrant
ER+/HER2–, stage I, II, and III breast cancer (adjuvant)source ↗
▲FDA ApprovalDatrowayApprovedFDA Decision
Datroway approved in U.S. for first-line treatment of metastatic triple negative breast cancer in patients not candidates for PD-1/PD-L1 inhibitors
metastatic triple negative breast cancersource ↗
▲IND ClearancelumipodlinIND
IND cleared by NMPA for lumipodlin + Tagrisso combination study
EGFR-mutated PD-L1 positive locally advanced or metastatic NSCLCsource ↗
◆PDUFA DateENHERTUApprovedRegulatory Filing
PDUFA date of May 18, 2026 for neoadjuvant sBLA
HER2 positive stage 2 or stage 3 breast cancer (neoadjuvant)source ↗
▲AdCom OutcomeTRUQAPApprovedAdvisory Committee
ODAC voted 7-1-1 that TRUQAP plus abiraterone and ADT has favorable benefit-risk profile
PTEN-deficient metastatic hormone-sensitive prostate cancersource ↗
◆PDUFA DateDatrowayApprovedRegulatory Filing
PDUFA date set for Q2 2026
metastatic triple-negative breast cancer (TNBC)source ↗
▲Partnership / LicensePTX-299Corporate
AstraZeneca exercised option for exclusive global license to PTX-299 from Pinetree
▲Partnership / LicenseCorporate
AstraZeneca closed strategic collaboration with CSPC for next-generation obesity and T2D therapies
obesity and type 2 diabetessource ↗
Past FDA Catalysts and PDUFA Decisions
How AZN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-16 | Truqap (capivasertib) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A84 / 100
Pipeline Score
$85.8B
Pipeline Value
$262.6B
Commercial Value
Fair Value
Valuation Signal
237
Drugs Scored
1.2x
rNPV / MCap
Top 1%
Large Pharma(rank 8 of 660)
Percentile Rank
AstraZeneca PLC earns an A-grade pipeline score (84/100), with $85.9B risk-adjusted pipeline value, led by Elecoglipron in Type 2 Diabetes Mellitus (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (20-F and 6-K), to Jun 2026; product lines: last four quarters to Jun 2026 (20-F and 6-K)) Revenue $61.4B x 4.3 = $262.6B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Farxiga | $8.2B | - | - |
| Tagrisso | $7.5B | - | - |
| Imfinzi | $6.9B | - | - |
| Ultomiris | $5.1B | - | - |
| Calquence | $3.8B | - | - |
| Lynparza | $3.3B | - | - |
| Symbicort | $2.9B | - | - |
| Fasenra | $2.1B | - | - |
| Strensiq | $2.0B | - | - |
| Soliris | $1.6B | - | - |
| Breztri | $1.3B | - | - |
| Crestor | $1.3B | - | - |
Top 12 of 30 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elecoglipron Small moleculeNCT07662044 | Type 2 Diabetes Mellitus | Phase 3 | RECRUITING | 5,500 | Jul 14, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every AZN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BREZTRI | uncontrolled asthma | Phase 3 | 2026-02-13 | BREZTRI improved lung function by 76mL (95% CI 57-94 mL, unadjusted p<0.001, as measured by morning pre-dose trough FEV1 over 24 weeks); 90mL (95% CI 72-108 mL, unadjusted p<0.001, as measured by FEV1 AUC0-3 over 24 weeks)Read More | Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory MedicineRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sharma ManiOfficer (See Remarks) | Buy | 20.233 19,287.699 held | $160.57 | 08/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AZN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 3.2 % (23.1 %) | 171.08 M | 915.70 K | 36.63% ( 245.50 K) |
AZN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-03-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AZN ranks across every disease it competes in
Competitive Position is a premium feature
See how AZN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAZN News
AZNAstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
AstraZeneca has inaugurated a new global strategic R&D center in Kendall Square, Cambridge, Massachusetts. This facility strengthens the company's existing presence in the area and aims to foster innovation by placing scientists in a leading life sciences ecosystem. The center is expected to enhance collaboration in genomic medicine and other research areas.
Read more →AZNSERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight
The SERD market is projected to grow significantly from 2026 to 2036, driven by advancements in treatment and increased awareness. AstraZeneca's recent approval of ETCAMAH (camizestrant) is expected to accelerate the adoption of oral SERDs. However, challenges persist, including the need for SERDs to prove their efficacy against established therapies.
Read more →AZNDaiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
Daiichi Sankyo and AstraZeneca have formed a clinical trial collaboration with Summit Therapeutics to assess the efficacy of Datroway® in combination with ivonescimab across various tumor types, including lung and breast cancers. The collaboration will commence with a phase 3 trial focusing on first-line treatment for triple negative breast cancer. This partnership aims to enhance treatment options for patients with these cancers.
Read more →AZNEccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)
Eccogene has received a $50 million milestone payment from AstraZeneca following the initiation of a Global Phase 3 program for Elecoglipron (AZD5004/ECC5004). This payment marks a significant step in the development of the drug, showcasing the partnership's progress. The Phase 3 program is crucial for the drug's potential approval and market entry.
Read more →AZNPolaris Rx Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service for Second Consecutive Year
Polaris Rx has been named the exclusive U.S. distributor for AstraZeneca's FluMist Home service for the 2026-2027 flu season, marking the second consecutive year of this partnership. This service allows individuals to conveniently order the flu vaccine online and have it delivered directly to their homes. The collaboration aims to improve access to flu vaccinations.
Read more →AZNSusan G. Komen® and AstraZeneca Partnership to Make Patient Navigation Available to All
Susan G. Komen has partnered with AstraZeneca to enhance patient navigation in breast cancer care. This initiative aims to integrate patient navigation into the national healthcare system, addressing barriers and improving access to timely treatments. The collaboration seeks to reduce patient stress and enhance adherence to cancer care plans across the nation.
Read more →AZNThe Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck's LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca's AZD0780, Aqur's AQR-008, and Others | DelveInsight
The PCSK9 inhibitors market is experiencing significant growth due to the approval of Merck's LIPFENDRA and the introduction of new oral therapies, including AstraZeneca's AZD0780. This expansion is driven by the increasing prevalence of hypercholesterolemia and cardiovascular diseases, leading to a higher demand for effective lipid-lowering treatments. The report highlights the potential for improved patient adherence and broader treatment options in this evolving market.
Read more →AZNAstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
AstraZeneca has finalized a global license agreement with Dizal Pharmaceutical for ZEGFROVY (sunvozertinib), an oral EGFR inhibitor for lung cancer. This agreement grants AstraZeneca worldwide rights to develop and commercialize the drug, which is already approved in the US and China for second-line treatment in adults.
Read more →AZNAstraZeneca results: H1 and Q2 2026
AstraZeneca reported strong financial results for H1 2026, with total revenue increasing by 9% compared to the previous year. Product sales reached $28.9 billion, reflecting an 8% growth. The company's core EPS also showed a positive trend, rising by 12%. However, collaboration revenue experienced a decline of 6%. Overall, the results indicate a solid performance despite some challenges.
Read more →AZNDizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy
Dizal has entered a global exclusive license agreement with AstraZeneca for Zegfrovy, an EGFR inhibitor for lung cancer. The deal includes a $600M upfront payment and potential milestone payments of up to $900M. Zegfrovy is already approved in China and the US for treating advanced NSCLC with specific mutations. AstraZeneca aims to leverage its oncology expertise to expand Zegfrovy's reach.
Read more →AZNHelix Announces Multi-Year Agreement with AstraZeneca to Support Genomic Research for Drug Discovery and Development
Helix has entered a multi-year agreement with AstraZeneca to provide access to its GenoSphere cohorts, which include extensive genomic and clinical data. This collaboration aims to enhance drug discovery and development by leveraging integrated clinico-genomic data. The partnership is expected to accelerate biomedical research and improve the development of targeted therapies.
Read more →AZN▲ +6.1%on this newsshared move
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
Abbisko Therapeutics has partnered with AstraZeneca to conduct a Phase I/II clinical trial for lumipodlin (ABSK043), an oral PD-L1 inhibitor, in combination with TAGRISSO® for treating non-small cell lung cancer (NSCLC). The trial aims to evaluate the safety and efficacy of this novel therapy for patients with EGFR mutations and high PD-L1 expression. The IND application for the study was recently approved by the National Medical Products Administration.
Read more →AZNAstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
AstraZeneca has formed a partnership with YMCA of the USA to tackle disparities in cancer care. This collaboration aims to enhance accessibility and improve health outcomes for communities. The initiative is expected to address critical gaps in healthcare services related to cancer treatment and support.
Read more →AZNLung Cancer Research Foundation and AstraZeneca Announce Open Call for Research Proposals with Focus on Small Cell Lung Cancer
The Lung Cancer Research Foundation and AstraZeneca have announced two research awards aimed at improving treatment outcomes for small cell lung cancer (SCLC). The awards, totaling $750,000, will support innovative strategies and patient advocacy efforts. Submissions for research proposals are open until July 15, 2026, with the goal of advancing understanding and treatment of this challenging cancer.
Read more →AZNDatroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Datroway® has received U.S. approval as the first TROP2 directed antibody drug conjugate. It is intended for first-line treatment of patients with metastatic triple negative breast cancer who are not eligible for PD-1/PD-L1 inhibitors. This approval marks a significant advancement in treatment options for this patient population.
Read more →AZNस्तन तथा फेफड़ों के कैंसर में एडवांस पैथोलॉजी के लिए एक स्थायी इकोसिस्टम को गति देने में सहायता करने के लिए AstraZeneca ने Roche Diagnostics Asia Pacific
AstraZeneca has partnered with Roche Diagnostics Asia Pacific to enhance digital pathology capabilities for cancer diagnostics. This collaboration aims to leverage AI technology to improve patient outcomes and diagnostic accuracy. The initiative is expected to significantly benefit the healthcare landscape in Asia Pacific, particularly in the management of cancer treatments.
Read more →AZNAstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer
AstraZeneca and Roche Diagnostics Asia Pacific have entered a three-year Memorandum of Understanding to enhance digital pathology capabilities across nine Asian markets. This collaboration aims to improve biomarker testing for breast and lung cancer through AI-powered solutions and educational initiatives. The partnership addresses significant gaps in diagnostic processes and aims to standardize and improve cancer care.
Read more →AZNFDA approves AstraZeneca’s new kind of hypertension drug
The FDA has approved AstraZeneca's Baxfendy, a novel hypertension treatment expected to generate over $5 billion annually. The drug, which targets a root cause of hypertension, shows promise in clinical trials and is anticipated to launch soon, although it poses competitive challenges for other biotech firms.
Read more →AZNTRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
The FDA's Oncologic Drugs Advisory Committee has recommended AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer. This recommendation is based on favorable results from the CAPItello-281 Phase III trial, which demonstrated a significant reduction in disease progression. The treatment addresses a critical need for patients with limited options and is the first targeted therapy for this cancer subtype.
Read more →AZNKoselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1
Koselugo (selumetinib) has been approved in Canada for adults with neurofibromatosis type 1 (NF1) suffering from symptomatic, inoperable plexiform neurofibromas. This approval follows positive results from the KOMET Phase III trial, which showed a 20% objective response rate in tumor size reduction. Experts highlight the significance of this treatment option for patients who previously had limited therapeutic choices.
Read more →About AstraZeneca PLC
HeadquartersCambridge
Founded1913
BIOPHARMAWATCH ELITE PLUS
Trade the next AZN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime